Pitfalls in Pharmacokinetic Modeling of Monoclonal Antibody Biodistribution in Man

  • Giuliano Mariani
  • Luigi Ferrante
  • Aldo Rescigno
Part of the NATO ASI Series book series (NSSA, volume 221)


Immunoscintigraphy employing radiolabeled monoclonal antibodies (MoAbs) specific for certain selected tumor-associated antigens (TAAs) is becoming increasingly accepted as a routine diagnostic procedure, particularly for staging patients with cancer. In fact, even though the diagnostic potentials of immunoscintigraphy have been explored for diverse applications including cardiovascular diseases (for the detection of thrombi or of damaged myocardial cells), oncology is certainly the field where clinical validation of this new imaging method has been most extensive [for a brief overview on the clinical usefulness of immunoscintigraphy and on some pharmacokinetic aspects concerning this new diagnostic procedure, see Mariani and Strober, 1990]. It is now widely acknowledged that tumor immunoscintigraphy is of great value in terms of both specificity (close to 100%) and sensitivity (about 75–80% on the average). In addition, one of the major advantages of this procedure has been shown to be the ability of detecting distant tumor lesions in about one-third of patients who are apparently “tumor-free” as classified by other, noninvasive diagnostic techniques; therefore, for some specific forms of cancer, immunoscintigraphy may be considered as a mandatory diagnostic procedure for correctly staging and monitoring patients, complementary to other techniques already well established in the clinical routine [Mariani et al., 1989].


Pharmacokinetic Analysis Biodistribution Study Plasma Space Tumor Compartment Multicompartmental Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Buraggi G.L., 1985. Radioimmunodetection of cancer. J. Nucl. Med. Allied Sci. 29: 261.PubMedGoogle Scholar
  2. Eger R.R., Covell D.G., Carrasquillo J.A., Abrams P.G., Foon K.A., Reynolds J.C., Schroff R.W., Morgan A.C., Larson S.M., Weinstein J.N.,. 1987. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res. 47: 3328.PubMedGoogle Scholar
  3. Gobuty A.H., Kim E.E., Weiner R.E., 1985. Radiolabeled monoclonal antibodies: radiochemical pharmacoldnetic and clinical challenges. J. Nucl. Med. 26: 546.PubMedGoogle Scholar
  4. Goodwin D.A., 1987. Pharmacokinetics and antibodies. J. Nucl. Med. 28: 1358.PubMedGoogle Scholar
  5. Griffin T.W., Bokhari F., Collins J., Stochl M., Bernier M., Gionet M., Siebecker D., Wetheimer M., Giroves E.S., Grenfield L., Houston L.L., Doherty P.W., Wilson J., 1989. A preliminary pharmacokinetic study of 111In-labeled 260F9 anti-(breast cancer) antibody in patients. Cancer Immunol. Immunother. 29: 43.CrossRefGoogle Scholar
  6. Halpern S.E., Haindl W., Beauregard J., Hagan P., Clutter M., Amox D., Merchant B., Unger M., Mongovi C., Bartholomew R., Jue R., Carlo D., Dillman R., 1988. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. Radiology 168: 529.PubMedGoogle Scholar
  7. Hayes D.F., Zalutsky M.R., Kaplan W., Noska M., Thor A., Colcher D., Kufe D.W., 1986. Pharmacoldnetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. Cancer Res. 46: 3157.PubMedGoogle Scholar
  8. Hnatowich D.J., Gionet M., Rusckowski M., Siebecker D.A., Roche J., Shealy D., Mattis J.A., Wilson J., McGann J., Hunter R.E., Griffin T., Doherty P.W., 1987. Pharmacokinetics of 111In-labeled OC-125 antibody in cancer patients compared with the 19–9 antibody. Cancer Res. 47: 6111.PubMedGoogle Scholar
  9. Kohler G., Milstein C., 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495.PubMedCrossRefGoogle Scholar
  10. Koizumi K., DeNardo G.L., DeNardo S.J., Hays M.T., Hines H.H., Scheibe P.O., Peng J.-S., Macey D.J., Tonami N., Hisada K., 1986. Multicompartmental analysis of the Idnetics of radioiodinated monoclonal antibody in patients with cancer. J. Nucl. Med. 27: 1243.PubMedGoogle Scholar
  11. Larson S.M., Carrasquillo J.A., Reynolds J.C., 1984. Radioimmunodetection and radioimmunotherapy. Cancer Invest. 2: 363.PubMedCrossRefGoogle Scholar
  12. Mariani G.,. 1987. A protocol for screening tumour radioimmunoscintigraphy agents. In: “Lectures and Symposia, 14th International Cancer Congress, vol. 6: Epidemiology, Prevention, Diagnosis.” Lapis K. and Eckardt S., eds.), page 329. Akademiai Kiadb, Budapest.Google Scholar
  13. Mariani G., Ferrante L., Rescigno A., 1986. Kinetic modeling for the analysis of digital images from tissue distribution studies of tumor radioimmunoscintigraphy agents. In: “Radioaktive Isotope in Klinik und Forschung, 17th (II).” ( Höfer R. and Bergmann H., eds.), page 741. Verlag H. Egerman, Wien.Google Scholar
  14. Mariani G., Mazzuca N., Molea N., Bianchi R., Donato L., 1985. Kinetic distribution studies in vivo of radioiodinated monoclonal preparations as a screening procedure for tumour immunoscintigraphy agents. In: “Immunoscintigraphy.” ( Donato L. and Britton K., eds.), page 83. Gordon & Breach, New York and London.Google Scholar
  15. Mariani G., Rosa C., Donato L.,. 1989. Comparison of the diagnostic sensitivity of tumor radioimmunoscintigraphy by means of an anti-CEA monoclonal antibody with other noninvasive diagnostic techniques. In: “Nuclear Medicine. Trends and Possibilities in Nuclear Medicine.” ( Schmidt H.A.E. and Buraggi G.L., eds.), page 527. Schattauer Verlag, Stuttgart.Google Scholar
  16. Mariani G., Strober W., 1990 Immunoglobulin metabolism. In: “F c Receptors and the Action of Antibodies.” ( Metzeger H., ed.), page 94. American Society for Microbiology, Washington, D.C.Google Scholar
  17. Marquardt D.W., 1963. An algorithm for least squares estimation of nonlinear parameters. SIAM J. 11: 431.Google Scholar
  18. Murray J.L., Lamki L.M., Shanken L.J., Blake M.E., Plager C.E., Benjamin R.S., Schweighardt S., Unger M.W., Rosenblum M.G., 1988. Immunospecific saturable clearance mechanisms for Indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans. Cancer Res. 48: 4417.PubMedGoogle Scholar
  19. Rescigno A., Bushe H., Brill A.B., Rusckowski M., Griffin T.W., Hnatowich D.J., 1990. Pharmacokinetic modeling of radiolabeled antibody distribution in man. Am. J. Physiol. Imaging 5: 141.PubMedGoogle Scholar
  20. Rescigno A., Gurpide E., 1973. Estimation of average times of residence, recycle, and interconversion of blood-borne compounds using tracer methods. J. Clin. Endocrinol. Metab. 36: 263.PubMedCrossRefGoogle Scholar
  21. Rescigno A., Lambrecht R.M., Duncan C.C., 1983. Mathematical methods in the formulation of pharmacokinetic models. In: “Tracer Kinetics and Physiologic Imaging.” ( Lambrecht R.M. and Rescigno A., eds.), page 59. Springer Verlag, Berlin.Google Scholar
  22. Rosenblum M.G., Murray J.L., Haynie T.P., Glenn H.J., Jahns M.F., Benjamin R.S., Frincke J.M., Carlo D.J., Hersh E.M., 1985. Pharmacokinetics of 111Inlabeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res. 45: 2382.PubMedGoogle Scholar
  23. Rosenblum M.G., Murray J.L., Lamki L., David G., Carlo D.J., 1987. Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies. Cancer Chemother. Pharmacol. 20: 41.Google Scholar
  24. Sheiner L.B., 1981. Extended least square fit (ELSFIT). Technical Report, Division of Clinical Pharmacology, University of California.Google Scholar
  25. Working Group Meeting, 1986. Radioimmunoimaging - Report. Hybridoma 5: 166.Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Giuliano Mariani
    • 1
  • Luigi Ferrante
    • 2
  • Aldo Rescigno
    • 3
  1. 1.CNR Institute of Clinical PhysiologySecond Medical Clinic of the University of PisaPisaItaly
  2. 2.Medical School of the University of AnconaAnconaItaly
  3. 3.School of PharmacyUniversity of ParmaParmaItaly

Personalised recommendations